Medigene AG (MDGEF)
OTC
Healthcare
Biotechnology
$2.59
▲ +0.00%
Market Cap
$38.2M
Sector
Healthcare
Industry
Biotechnology
Beta
1.36
52-Wk Range
0.1-2.59
CEO
Ralph Schaefer
Country
DE
Currency
USD
Medigene AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Munich, BY, DE. The stock last traded at $2.59, up 0.00% on the session, giving a market capitalisation of $38.2M. On trailing twelve-month figures it carries a trailing P/E of -1.72, a net margin of -268.1%. Its beta of 1.36 implies it has historically moved more than the broad market.
Valuation & profitability (TTM)
P/E
-1.72
Price / Sales
5.55
Price / Book
1.32
EV / EBITDA
-1.80
Gross margin
72.8%
Operating margin
-267.6%
Net margin
-268.1%
Return on equity
—
Debt / equity
0.14
Current ratio
2.53
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
87
IPO date
2013-06-17
Headquarters
Munich, BY, DE
About Medigene AG
Medigene AG is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of T-cell therapies for the treatment of cancer. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
Comparable companies
Medigene AG is most often compared with the following Healthcare names:
More research on MDGEF
Open full interactive analysis & DCF →